Not Signed In - Spectrum Pharmaceuticals Initiates Phase 2b Trial For Ozarelix In Patients With Benign Prostate Hypertrophy
Fri, 26 Jan 2007 08:00 AM EST
... Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that the first patient has been dosed in the company's Phase 2b study of ozarelix in the U.S. in patients with benign prostate hypertrophy (BPH). The trial will be conducted in accordance with the protocol recently accepted by the U.S. Food and Drug Administration (FDA). [click link for full article] ...
Related Topics
- Clinical Trials
- Prostate Diseases
- Prostate, Benign Hypertrophy
- Prostate
- Prostate Cancer
- Benign Tumors
- Benign Tumor
- Biopsy of the Prostate
- Autism Spectrum Disorders
- Enlarged Prostate/Benign Prostatic Hyperplasia
- Prostate Enlargement: Benign Prostatic Hyperplasia
- Ribavirin and Interferon alfa-2b, recombinant
- Autism
- Interferon Alfa-2b
- BPH
- Hypertrophy
- Peginterferon alfa-2b
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Benign Prostatic Hyperplasia
email this page
print this page
bookmark this page
feedback on this page
